Listen to two experts discuss the latest in immune checkpoint modulation in advanced HCC.
This activity is intended for oncologists and gastroenterologists who treat patients with HCC.
The goal of this activity is to discuss how immune checkpoint inhibitors may alter the landscape in the treatment of advanced HCC management.
Approximate Time to Complete: 30 minutes
Course Available Beginning: Mar. 24, 2017
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding emerging clinical trial data on the use of biomarkers and immune checkpoint inhibitors in the management of hepatocellular carcinoma (HCC)
- Have increased knowledge regarding the potential impact of recent clinical data on treatment strategies for patients with HCC in the community oncology setting